Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

October 15, 2025

Study Completion Date

December 15, 2025

Conditions

Hemophilia A With InhibitorHemophilia B With Inhibitor

Interventions

DRUG

KN057

KN057 will be administered subcutaneously once a week.

Trial Locations (1)

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Suzhou Alphamab Co., Ltd.

INDUSTRY